retatrutide clinical trials status FDA Approval Status: July 2026 Update First phase 3 data for

For starters, TRT is much more affordable than peptide therapy

These medications, he said, are extremely disruptive to the body and should not be used outside of a specific, regulated set of serious medical reasonsnamely, life-compromising obesity and its related health consequences, she recalled

Progressive proximal muscle weakness (affecting shoulders and hips more than hands and feet) may indicate an inflammatory myopathy or other serious neuromuscular condition that requires investigation beyond simply attributing symptoms to GLP-1 therapy

What we are seeing is a signal that it may slow some of the biological processes associated with aging

Its also worth mentioning that only 5% to 10% of patients discontinue Wegovy due to gastrointestinal side effects , indicating that while these symptoms are common, they are often manageable with appropriate support